Outpatient Performed Pterygium Surgery Study

Conditions

• Pterygium of Conjunctiva and Cornea

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• 5-Fluorouracil — DRUG
  5-fluorouracil is an antimetabolite that is commonly used in glaucoma surgery to prevent postoperative scaring.
• Bevacizumab — DRUG
  Bevacizumab is an anti-VEGF antibody that is commonly used to prevent or treat neovascularization in retinal disorders.
• Normal saline — DRUG
  Normal saline will be used as the placebo.

Study Details

This is a randomized controlled trial of postoperative bevacizumab or 5-fluorouracil subconjunctival injections vs placebo for the recurrence of pterygia after excision using conjunctival autograft.

Key Dates

First listed

Jan 31, 2017

Start date

Mar 1, 2020

Status verified

Aug 2021

Primary completion

Mar 1, 2020

Completion

Mar 1, 2020

Study Design

Enrollment

0 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Placebo Comparator: Placebo
  Patients will receive 0.1mL of normal saline injected subconjunctival in the area of the excised pterygium and 1 and 2 months postoperative.
• Active Comparator: 5-Fluorouracil
  Patients will receive 0.1mL of 5-Fluorouracil, 5mg/0.1mL, injected subconjunctival in the area of the excised pterygium and 1 and 2 months postoperative.
• Active Comparator: Bevacizumab
  Patients will receive 0.1mL of bevacizumab, 2.5mg/0.1mL, injected subconjunctival in the area of the excised pterygium and 1 and 2 months postoperative.

Primary Outcome Measure

Recurrence [ Time Frame: 3 months ]